Insider Buying: AnaptysBio, Inc. (NASDAQ:ANAB) Director Buys 6,646 Shares of Stock

AnaptysBio, Inc. (NASDAQ:ANAB) Director Ecor1 Capital, Llc purchased 6,646 shares of the stock in a transaction on Thursday, January 2nd. The shares were purchased at an average cost of $12.95 per share, for a total transaction of $86,065.70. Following the acquisition, the director now directly owns 7,880,094 shares of the company’s stock, valued at approximately $102,047,217.30. This represents a 0.08 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website.

Ecor1 Capital, Llc also recently made the following trade(s):

• On Monday, December 30th, Ecor1 Capital, Llc acquired 65,184 shares of AnaptysBio stock. The shares were purchased at an average price of $12.92 per share, for a total transaction of $842,177.28.

AnaptysBio Stock Up 9.3 %

AnaptysBio stock opened at $14.60 on Friday. AnaptysBio, Inc. has a twelve month low of $12.51 and a twelve month high of $41.31. The company’s 50-day moving average price is $19.75 and its 200-day moving average price is $28.43. The company has a market cap of $444.26 million, a PE ratio of -2.40 and a beta of -0.02.

AnaptysBio (NASDAQ:ANAB) last issued its quarterly earnings data on Tuesday, November 5th. The biotechnology company reported ($1.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.72) by $0.58. The business had revenue of $30.02 million for the quarter, compared to the consensus estimate of $7.92 million. AnaptysBio had a negative return on equity of 287.94% and a negative net margin of 289.75%. As a group, sell-side analysts expect that AnaptysBio, Inc. will post -6.02 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have commented on ANAB. Wedbush reissued an “outperform” rating and set a $40.00 price target (down from $42.00) on shares of AnaptysBio in a report on Wednesday, December 11th. BTIG Research downgraded AnaptysBio from a “buy” rating to a “neutral” rating in a research note on Monday, December 2nd. Truist Financial dropped their price target on AnaptysBio from $30.00 to $20.00 and set a “hold” rating for the company in a research note on Wednesday, December 18th. Guggenheim reduced their price objective on shares of AnaptysBio from $90.00 to $36.00 and set a “buy” rating on the stock in a research report on Thursday, December 12th. Finally, JPMorgan Chase & Co. cut their target price on shares of AnaptysBio from $66.00 to $36.00 and set an “overweight” rating for the company in a research note on Thursday, December 19th. Four investment analysts have rated the stock with a hold rating and eight have issued a buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $41.45.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of the company. Frazier Life Sciences Management L.P. raised its stake in shares of AnaptysBio by 140.7% in the second quarter. Frazier Life Sciences Management L.P. now owns 2,165,591 shares of the biotechnology company’s stock valued at $54,270,000 after acquiring an additional 1,265,891 shares during the period. FMR LLC grew its holdings in AnaptysBio by 15.3% during the 3rd quarter. FMR LLC now owns 3,309,175 shares of the biotechnology company’s stock valued at $110,857,000 after purchasing an additional 438,557 shares during the last quarter. Jennison Associates LLC purchased a new stake in AnaptysBio in the 3rd quarter worth about $8,874,000. Victory Capital Management Inc. raised its position in AnaptysBio by 677.9% in the 3rd quarter. Victory Capital Management Inc. now owns 237,250 shares of the biotechnology company’s stock worth $7,948,000 after purchasing an additional 206,750 shares during the period. Finally, Assenagon Asset Management S.A. lifted its stake in AnaptysBio by 55.1% in the third quarter. Assenagon Asset Management S.A. now owns 475,446 shares of the biotechnology company’s stock worth $15,927,000 after purchasing an additional 168,813 shares during the last quarter.

AnaptysBio Company Profile

AnaptysBio, Inc, a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis.